Treatment Information

Back

Ovarian Cancer treatment details. Immunotherapy.

University of Alabama School of Medicine, Birmingham, AL, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Birmingham, AL
Treatments:ImmunotherapyHospital:University of Alabama School of Medicine
Drugs:Journal:Link
Date:Jun 2014

Description:

Patients:
This phase 2 study involved 20 recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer patients who had received prior platinum-based chemotherapy. The median patient age was 57 years.

Treatment:
Patients received immunotherapy with EGEN-001, a form of interleukin-12 (IL-12) that stimulates the immune system to attack cancer cells.

Toxicities:
The most severe toxicities were of grade 3 and included nausea and vomiting (2 patients), anemia (1 patient), and decreased lymphocyte count (1 patient). Grade 1-2 fever, chills, abdominal pain, and anemia were also reported.

Results:
The median overall survival was 9.17 months.

Correspondence: Dr. Ronald D. Alvarez; email: [email protected]



Back